These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Implementation of CYP2C19 genotyping to guide proton pump inhibitor use at an academic health center. Cicali EJ; Elchynski A; Thomas CD; Alam B; Dalton R; Davis R; Eken E; Estores D; Nguyen K; Cavallari LH; Wiisanen K Am J Health Syst Pharm; 2023 Jul; 80(15):994-1003. PubMed ID: 37166240 [TBL] [Abstract][Full Text] [Related]
8. Identification of high-impact gene-drug pairs for pharmacogenetic testing in Alberta, Canada. Fan M; Yarema MC; Box A; Hume S; Aitchison KJ; Bousman CA Pharmacogenet Genomics; 2021 Feb; 31(2):29-39. PubMed ID: 32826605 [TBL] [Abstract][Full Text] [Related]
9. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Bousman CA; Jaksa P; Pantelis C Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243 [TBL] [Abstract][Full Text] [Related]
10. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics. Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A; OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544 [TBL] [Abstract][Full Text] [Related]
11. Implementation of CYP2C19 and CYP2D6 genotyping to guide antidepressant use in a large rural health system. Petry NJ; Van Heukelom J; Schultz AJ; Jacobsen K; Baye JF; Mills S; Figueroa DM; Massmann A Am J Health Syst Pharm; 2024 Aug; 81(16):723-732. PubMed ID: 38546726 [TBL] [Abstract][Full Text] [Related]
12. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514 [TBL] [Abstract][Full Text] [Related]
13. Implementing a personalized medicine program in a community health system. Dressler LG; Bell GC; Ruch KD; Retamal JD; Krug PB; Paulus RA Pharmacogenomics; 2018 Nov; 19(17):1345-1356. PubMed ID: 30345883 [TBL] [Abstract][Full Text] [Related]
14. Implementing pharmacogenetic testing to optimize proton-pump inhibitors use among Indian population based on CPIC-CYP2C19-PPI dosing guidelines: The need of the hour. Chenchula S; Atal S; Jhaj R; Uppugunduri CRS Indian J Pharmacol; 2024 Jul; 56(4):277-284. PubMed ID: 39250625 [TBL] [Abstract][Full Text] [Related]
15. Determining the potential clinical value of panel-based pharmacogenetic testing in patients with chronic pain or gastroesophageal reflux disease. Elchynski AL; Cicali EJ; Ferrer Del Busto MC; Hamilton A; Chang KL; Schmidt SO; Weiner B; Davis R; Estores D; Max Smith D; Wiisanen K; Johnson JA; Cavallari LH Pharmacogenomics J; 2021 Dec; 21(6):657-663. PubMed ID: 34075203 [TBL] [Abstract][Full Text] [Related]
16. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US. Hertz DL; Bousman CA; McLeod HL; Monte AA; Voora D; Orlando LA; Crutchley RD; Brown B; Teeple W; Rogers S; Patel JN Am J Health Syst Pharm; 2024 Aug; 81(16):672-683. PubMed ID: 38652504 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic Testing in Patients with Autism Spectrum Disorder Evaluated in a Precision Medicine Clinic. Goodson R; Wagner J; Sandritter T; Staggs VS; Soden S; Nadler C J Dev Behav Pediatr; 2023 Oct-Nov 01; 44(8):e505-e510. PubMed ID: 37807195 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of population-level pharmacogenetic actionability in Alabama. Davis BH; Williams K; Absher D; Korf B; Limdi NA Clin Transl Sci; 2021 Nov; 14(6):2327-2338. PubMed ID: 34121327 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee. Vassy JL; Stone A; Callaghan JT; Mendes M; Meyer LJ; Pratt VM; Przygodzki RM; Scheuner MT; Wang-Rodriguez J; Schichman SA; Genet Med; 2019 Feb; 21(2):382-390. PubMed ID: 29858578 [TBL] [Abstract][Full Text] [Related]
20. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice. Rosenman MB; Decker B; Levy KD; Holmes AM; Pratt VM; Eadon MT Value Health; 2017 Jan; 20(1):54-59. PubMed ID: 28212969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]